Awawu Igbinadolor, MD
Internal medicine, Member of Royal College of
Physicians (MRCP), United Kingdom
Dr. Igbinadolor was trained at the University of Benin Medical School in Nigeria and the Royal Free Hospital in London. Her residency was with MCP-Hahnemann University in Philadelphia.
During the Pandemic, Dr. Igbinadolor was one of the highest enrolling investigators on a study evaluating a groundbreaking mAB treatment for COVID-19. As a result of her contribution, she was a signatory on the findings submitted to the FDA for the COVID treatment’s Emergency Use Authorization.
She was also one of the top performing investigators on a phase I COVID treatment study, including the first and second in human dose of the landmark investigational treatment.